Mortality at 120 days after prostatic biopsy: A population-based study of 22,175 men

International Journal of Cancer

Volumn 123, Issue 3, 2008, Pages 647-652

  Gallina, Andrea ^a,b   Suardi, Nazareno ^a,b   Montorsi, Francesco ^b   Capitanio, Umberto ^a,b   Jeldres, Claudio ^a   Saad, Fred ^a   Graefen, Markus ^c   Shariat, Shahrokh F ^d   Widmer, Hugues ^a   Arjane, Philippe ^a   Péloquin, François ^a   Perrotte, Paul ^a   Karakiewicz, Pierre I ^a,e  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY OF HAMBURG   (Germany)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Diagnosis; Mortality; Nomogram; Prostate biopsy; Prostate cancer

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; COMORBIDITY; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RISK ASSESSMENT; TRANSRECTAL ULTRASONOGRAPHY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BIOPSY; COMORBIDITY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NOMOGRAMS; ODDS RATIO; PROSTATE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 46049111446     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23559     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA: Cancer J Clin 2007;57:43-66.
2. Smith RA, Cokkinides V, Eyre HJ American Cancer Society guidelines for the early detection of cancer, 2006. CA: Cancer J Clin 2006; 56:11-25 (quiz 49-50).
3. Walz J, Graefen M, Chun FK, Erbersdobler A, Haese A, Steuber T, Schlomm T, Huland H, Karakiewicz PI. High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur Urol 2006;50:498-505.
4. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA, Jr. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004;350:2239-46.
5. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, Parnes HL, Coltman CA, Jr. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005;294:66-70.
6. Nadler RB, Loeb S, Roehl KA, Antenor JA, Eggener S, Catalona WJ. Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years. J Urol 2005;174:2154-7 (discussion 7).
7. Elabbady AA, Khedr MM. Extended 12-core prostate biopsy increases both the detection of prostate cancer and the accuracy of Gleason score. J Urol 2006;49:49-53 (discussion).
8. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003;349:335-42.
9. Saad A, Hanbury DC, McNicholas TA, Boustead GB. Acute periprostatic haematoma following a transrectal ultrasound-guided needle biopsy of the prostate. Prostate Cancer Prostatic Dis 2002;5:63-4.
10. Seymour MA, Oesterling JE. Anterior rectal wall hematoma: complication of transrectal ultrasound-guided biopsy of prostate. Urology 1992;39:177-81.
11. Teichman JM, Tsang T, McCarthy MP. Osteitis pubis as a complication of transrectal needle biopsy of the prostate. J Urol 1992; 148:1260-1.
12. Borer A, Gilad J, Sikuler E, Riesenberg K, Schlaeffer F, Buskila D. Fatal Clostridium sordellii ischio-rectal abscess with septicaemia complicating ultrasound-guided transrectal prostate biopsy. J Infect 1999;38:128-9.
13. Sohlberg OE, Chetner M, Ploch N, Brawer MK. Prostatic abscess after transrectal ultrasound guided biopsy. J Urol 1991;146:420-2.
14. Fradet V, McCormack M, Perrotte P, Karakiewicz P, Saad F. An epidural abscess following transrectal ultrasound-guided biopsies of the prostate. Can J Urol 2005;12:2899-900.
15. Basaran G. Endocarditis prophylaxis for transrectal prostatic biopsy. JAMA 1998;280:1908.
16. Irani J, Roblot F, Becq Giraudon B, Dore B. Acute bacterial endocarditis secondary to transrectal ultrasound-guided prostatic biopsy. Scand J Urol Nephrol 2002;36:156-7.
17. Davidson AJ, Webb DR, Lawrentschuk N, Jennens ID, Sutherland M. Multi-resistant Escherichia coli sepsis following transrectal ultrasound-guided prostate biopsy. Br J Hosp Med (Lond) 2006;67:98-9.
18. Binsaleh S, Al-Assiri M, Aronson S, Steinberg A. Septic shock after transrectal ultrasound guided prostate biopsy. Is ciprofloxacin prophylaxis always protecting? Can J Urol 2004;11:2352-3.
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
20. D'Hoore W, Sicotte C, Tilquin C. Risk adjustment in outcome assessment: the Charlson comorbidity index. Methods Inf Med 1993;32: 382-7.
21. Hens N, Aerts M, Molenberghs G. Model selection for incomplete and design-based samples. Stat Med 2006;25:2502-20.
22. Wheeler AP, Bernard GR. Treating patients with severe sepsis. The New N Engl J Med 1999;340:207-14.
23. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, Spangberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami HO, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352:1977-84.
24. Stuart ME, Strite SA. Radical prostatectomy versus watchful waiting. N Engl J Med 2005;353:1298-300 (author reply-300).
25. Marantz PR, Hall CB, Derby CA. Radical prostatectomy versus watchful waiting. N Engl J Med 2005;353:1298-300 (author reply-300).
26. Alibhai SM, Naglie G, Nam R, Trachtenberg J, Krahn MD. Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol 2003;21:3318-27.
27. Schwartz KL, Alibhai SM, Tomlinson G, Naglie G, Krahn MD. Continued undertreatment of older men with localized prostate cancer. Urology 2003;62:860-5.
28. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095-101.